Obesity Drugs: Oral Options Rise Beyond GLP-1 Weight Loss
The Weight Loss Revolution: Beyond GLP-1s, a New Era of Personalized Metabolic Health Nearly 42% of American adults are now considered obese, a figure that’s not just a public health crisis, but a rapidly evolving market. While injectable GLP-1 receptor agonists like Ozempic and Wegovy have dominated headlines, a quiet revolution is underway – one … Read more